|
October 24, 2008
VioQuest Pharmaceuticals Provides Strategic Alternatives Review and Operations Update
September 10, 2008
VioQuest Pharmaceuticals Receives 510(k) Response from FDA for Xyfid™
August 26, 2008
VioQuest Pharmaceuticals Announces Issuance of New U.S. Patent for Lenocta™
August 19, 2008
VioQuest Pharmaceuticals Announces Second Quarter 2008 Financial Results and Corporate Highlights
July 30, 2008
VioQuest Pharmaceuticals’ VQD-002 Named One of 10 Most Promising Oncology Projects by Windhover
July 21, 2008
VioQuest Pharmaceuticals Appoints Christopher P. Schnittker, CPA, as Chief Financial Officer
July 1, 2008
VioQuest Pharmaceuticals Submits 510(k) Application to FDA for Xyfid™, a Novel Topical Agent for the Treatment of Various Skin Disorders
June 2, 2008
VioQuest Pharmaceuticals Presents Phase 1 Data Showing Promising Immune Response and Safety Profile of Lenocta™
May 19, 2008
VioQuest Pharmaceuticals Announces Upcoming Lenocta™ Oral Presentation at the American Society of Clinical Oncology Annual Meeting
May 14, 2008
VioQuest Pharmaceuticals Announces First Quarter 2008 Financial Results
May 7, 2008
VioQuest Pharmaceuticals Announces Issuance of U.S. Patent
April 29, 2008
VioQuest Pharmaceuticals Announces New Trading Symbol
April 16, 2008
VioQuest Pharmaceuticals’ Novel Akt Inhibitor VQD-002 is Synergistic with Various Cancer Therapies in Preclinical Studies
April 14, 2008
VioQuest Pharmaceuticals Names Vernon L. Alvarez, Ph.D. as Vice President, Research & Development and Announces Resignation of Chief Scientific Officer
April 10, 2008
VioQuest Pharmaceuticals Completes Final Closing of Previously Announced Private Placement
March 31, 2008
VioQuest Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
March 20, 2008
VioQuest Pharmaceuticals Announces Initial Closing of Private Placement
March 18, 2008
VioQuest Pharmaceuticals Announces Presentations at Annual Meeting of the American Association for Cancer Research
March 10, 2008
Clinical Data on Lenocta™, a Protein Tyrosine Phosphatase Inhibitor in Development at VioQuest Pharmaceuticals, Accepted for Oral Presentation at ASCO
February 26, 2008
VioQuest Pharmaceuticals Enters Into Clinical Trial Agreement for Novel Akt Inhibitor VQD-002 with the National Cancer Institute
February 4, 2008
FDA Grants Orphan Drug Designation for Novel Akt Inhibitor VQD-002 in Multiple Myeloma
January 23, 2008
VioQuest Pharmaceuticals to Present at Two Investor Conferences in February
January 22, 2008
Novel Akt Inhibitor VQD-002 Shown to Reverse Cisplatin Resistance in Ovarian Cancer
|
